Literature DB >> 791317

Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties.

D J Boullin, D G Grahame-Smith, R P Grimes, H F Woods.   

Abstract

1 Previous work showed that platelets from patients receiving chlorpromazine (CPZ) have an enhanced aggregation response to 5-HT. This was caused by an action of CPZ on the platelets, a factor borne by the plasma, or both. 2 Therefore we studied 5-HT induced aggregation of platelets from CPZ treated patients resuspended in normal plasma and from normal subjects resuspended in CPZ plasma. 3 Aggregation responses of normal platelets to 5-HT were not enhanced by resuspension either in normal plasma or in CPZ plasma. In addition the enhanced responses of platelets from CPZ treated patients did not revert to normal after resuspension in normal plasma. 4 It is concluded that the enhanced aggregation response to 5-HT seen after CPZ treatment is due to a change in the properties of the platelets rather than a factor in the plasma.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 791317      PMCID: PMC1402505          DOI: 10.1111/j.1365-2125.1975.tb00469.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Technical methods. A simple method for the isolation of blood platelets.

Authors:  P Ganguly; W J Sonnichsen
Journal:  J Clin Pathol       Date:  1973-08       Impact factor: 3.411

2.  Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.

Authors:  D J Boullin; H F Woods; R P Grimes; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

3.  The action of extracellular cations on the release of the sympathetic transmitter from peripheral nerves.

Authors:  D J Boullin
Journal:  J Physiol       Date:  1967-03       Impact factor: 5.182

4.  5-Hydroxytryptamine uptake and release in relation to aggregation of rabbit platelets.

Authors:  H R Baumgartner
Journal:  J Physiol       Date:  1969-04       Impact factor: 5.182

5.  The relation between the 5-hydroxytryptamine content and aggregation of rabbit platelets.

Authors:  H R Baumgartner; G V Born
Journal:  J Physiol       Date:  1969-04       Impact factor: 5.182

  5 in total
  5 in total

1.  The reliability of 5-hydroxytryptamine induced platelet aggregation responses in schizophrenic patients treated with neuroleptic drugs.

Authors:  J M Knox; M W Orr; R Allen; M G Gelder; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

Review 2.  Assessment of anti-psychotic drugs.

Authors:  A V Mackay
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

3.  Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41,468), a selective 5-HT2-receptor antagonist. 1982.

Authors:  F de Clerck; J L David; P A Janssen
Journal:  Agents Actions       Date:  1994-12

4.  Platelet shape change in patients with psychiatric disorders and treated with phenothiazines, thioxanthines, butyrophenones, benzodiazepines, tricyclic antidepressants and beta-adrenergic blocking agents.

Authors:  D J Boullin
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

5.  Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.

Authors:  F de Clerck; J L David; P A Janssen
Journal:  Agents Actions       Date:  1982-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.